Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Analyzing current practice patterns: lessons from Amgen's Project ChemoInsight.

N A Hayes1

  • 1Amgen Inc., Thousand Oaks, CA, USA. nhayes@amgen.com

Oncology Nursing Forum
|April 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fc epsilon RI-mediated chloride uptake by rat mast cells: modulation by chloride transport inhibitors in relation to histamine secretion.

British journal of pharmacology·1997
Same author

Inhibitors of nitric oxide synthase in human skin.

The Journal of investigative dermatology·1996
Same author

IgE-receptor activated chloride uptake in relation to histamine secretion from rat mast cells.

British journal of pharmacology·1994
Same author

Human basophil degranulation is not triggered by very dilute antiserum against human IgE.

Nature·1993
Same author

Further studies on the actions of endothelin-1 on blood flow in human skin.

The British journal of dermatology·1992
Same author

Comparison of infrared and helium-neon lasers in the measurement of blood flow in human skin by the laser-Doppler technique.

Skin pharmacology : the official journal of the Skin Pharmacology Society·1992
Same journal

Exploring Information Needs of Patients With Cancer and Family Caregivers: A Descriptive and Network Analysis of End-of-Life Inquiries.

Oncology nursing forum·2026
Same journal

Postoperative Physiologic Comfort Management for Patients With Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy.

Oncology nursing forum·2026
Same journal

Exploring Racial Disparities in Uterine Cancer Survival: A 20-Year, Single-Site Analysis.

Oncology nursing forum·2026
Same journal

What I See as an Editor: The Reach of Nurse-Led Intervention Oncology Research.

Oncology nursing forum·2026
Same journal

Trends and Hot Spots in Cancer Family Resilience: A Bibliometric and Visualization Study.

Oncology nursing forum·2026
Same journal

Seven-Year Cognitive Trajectories in Older Adult Cancer Survivors: Findings From a National Cohort Study.

Oncology nursing forum·2026
See all related articles

Many breast cancer patients face chemotherapy dose delays or reductions, particularly older adults. Neutropenia is a common cause, highlighting the need for better management strategies.

Area of Science:

  • Oncology
  • Clinical Pharmacy
  • Cancer Care

Background:

  • Chemotherapy dose intensity is crucial for breast cancer treatment efficacy.
  • Suboptimal dosing can arise from various clinical factors.
  • Understanding patterns of dose modification is essential for improving patient outcomes.

Purpose of the Study:

  • To retrospectively review chemotherapy dose and dose intensity in breast cancer patients.
  • To identify factors associated with dose delays and reductions.

Main Methods:

  • Retrospective chart review of 20,106 breast cancer patients across 1,135 US oncology practices.
  • Analysis of chemotherapy dose delivery, including dose intensity, reductions, and delays.
  • Identification of neutropenia as a frequent cause for dose modifications.

Related Experiment Videos

Main Results:

  • 18.4% of patients did not achieve dose intensity, 25.7% experienced dose reductions, and 43.1% had dose delays.
  • Patients aged 65 and older were more likely to experience dose delays, reductions, and suboptimal dose intensity.
  • Neutropenia was frequently cited as the reason for chemotherapy dose delays and reductions.

Conclusions:

  • A significant proportion of breast cancer patients encounter chemotherapy dose delays or reductions.
  • Neutropenia management, including primary and secondary prophylaxis, requires consistent guidelines.
  • Nursing interventions can positively impact patient adherence to prescribed chemotherapy regimens.